Ridding the world of Covid-19 is a lucrative enterprise.
As analysts divvy up the multibillion-dollar rewards in line for the leaders in the race to roll out the first pandemic vaccines, no one is forgetting to track just how much the top company founders have on the line now as stock prices gyrate ever higher.
Bloomberg, which tracks these numbers with missionary zeal, puts Sahin’s net worth today at $5.1 billion following the most recent rise of BioNTech’s $BNTX share price. The biotech’s partner, Pfizer, is aggressively pushing ahead with plans to get the first approved vaccine in play, and Bernstein believes that will put the two collaborators in line for the largest market share for next year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,700+ biopharma pros reading Endpoints daily — and it's free.